RetinalGenix Technologies (RTGN) Total Non-Current Liabilities (2022 - 2026)
RetinalGenix Technologies (RTGN) reported Total Non-Current Liabilities of $1.7 million for Q1 2026, up 47.71% on a YoY basis from $1.2 million in Q1 2025, and down 5.53% sequentially from $1.8 million in Q4 2025.
RetinalGenix Technologies (RTGN) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 5 years of Total Non-Current Liabilities data on file, last reported at $1.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 47.71% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 47.71% YoY), and the FY2025 full-year result was $1.8 million, up 81.67% from the prior year.
- Total Non-Current Liabilities retreated to $1.7 million in Q1 2026, from $1.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.8 million in Q4 2025 to a low of $459804.0 in Q2 2022.
- A 5-year average of $1.3 million and a median of $1.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities soared 110.05% in 2023 and retreated 14.76% in 2025, its largest moves.
- Tracing RTGN's Total Non-Current Liabilities over 5 years: stood at $959815.0 in 2022, then slipped by 1.2% to $948279.0 in 2023, then climbed by 6.48% to $1.0 million in 2024, then jumped by 81.67% to $1.8 million in 2025, then fell by 5.53% to $1.7 million in 2026.
- Business Quant data shows RTGN's Total Non-Current Liabilities at $1.7 million in Q1 2026, $1.8 million in Q4 2025, and $1.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 3.53 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 9.85 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.57 Bn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.73 Mn |
| Dec 31, 2025 | 1.83 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.44 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 948,279.00 |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 965,824.00 |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 959,815.00 |
| Jun 30, 2022 | 459,804.00 |